The FDA and BioGen did NOT want you to know THIS about their latest Alzheimer drug collusion. Ep. 13

Who’s side is the FDA on anyway? BioGen has released a second attempt at an Alzheimer drug that isn’t much better than the first one that hit the market at $58,000 per year! Doesn’t seem like the agencies in place are doing much to prevent extreme capitalization.